CJC-1295 NO DAC + Ipamorelin specifications and research profile
Specifications summary
| Designation | Two-component GHRH/GHS research blend |
|---|---|
| Also known as | CJC-1295 NO DAC + Ipamorelin |
| Sequence / composition | 5mg CJC-1295 NO DAC + 5mg Ipamorelin per vial |
| Strength | 10mg × 10 vials |
| Presentation | 10-vial case |
| Purity | 99%+ HPLC |
| Storage | Store refrigerated at 2-8 C, protected from light. |
| COA | Batch document added when available |
Description and research context
This product combines two separately defined research components rather than forming a new molecular entity: a no-DAC modified-GRF material and the pentapeptide secretagogue Ipamorelin.
The blend is intended for controlled combination-versus-component comparisons across GHRH- and GHS-receptor assay systems. Component literature does not establish a single mechanism for the mixture.
Applications in research
- Blend-versus-component receptor-response comparisons
- GHRH- and GHS-receptor pathway assay design
- Analytical verification of two-component blend consistency
Precautions and interpretation
For controlled laboratory research only. Not for human or veterinary use. The cited findings come from specific biochemical, cellular, structural or preclinical models and must not be treated as usage guidance or evidence of a defined outcome outside those models.
CJC-1295 NO DAC + Ipamorelin research record
Clear product, batch, storage, dispatch and document information for this 10-vial case.
Research context
A 10mg research blend combining 5mg CJC-1295 NO DAC and 5mg Ipamorelin for controlled dual-component signalling comparisons.
Product record
The listing identifies the presentation, specification, storage record, dispatch status, and COA availability for the relevant product or batch.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.